SARS CoV 2 News and Research

RSS

Antidepressant fluoxetine (Prozac) suppresses replication of SARS-CoV-2

A study conducted by researchers at Julius-Maximilians-Universität Würzburg has shown that the antidepressant agent fluoxetine may be an effective drug for the early treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among at-risk groups.

16 Jun 2020

Multi-institutional study examines neuroimaging findings in COVID-19 patients

A new multi-institutional study published in the journal Radiology identifies patterns in abnormal brain MRI findings in patients with COVID-19.

16 Jun 2020

Antibody cocktail with potential to treat COVID-19 identified

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

16 Jun 2020

Life saving drug found for COVID-19 patients on ventilators

Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.

16 Jun 2020

Why improved pneumonia diagnosis is needed now more than ever

News-Medical speaks to Dr. William La Via about why improved pneumonia diagnosis is vital, especially in the wake of the COVID-19 pandemic.

16 Jun 2020

Many Americans face high out-of-pocket medical costs for COVID-19 hospitalizations

If past hospitalizations for pneumonia and other respiratory illnesses are any guide, many Americans could face high out-of-pocket medical costs for COVID-19 hospitalizations despite the fact that many insurers have waived their cost-sharing requirements, a study from researchers at Johns Hopkins Bloomberg School of Public Health suggests.

16 Jun 2020

Study reports structure of enzyme activator for high pathogenic avian influenza

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the current pandemic of COVID-19, is the focus of many investigators seeking to find an effective vaccine or therapeutic. Among the potential targets are various protease enzymes suspected of allowing the virus to gain entry to host cells and establish a successful infection.

16 Jun 2020

SARS-CoV-2 mutation reduces S1 shedding, increases infective potential

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the seventh coronavirus known to infect humans. SARS-CoV-2 emerged in the last month of 2019 in Wuhan, China, sparking off the ongoing COVID-19 pandemic. This virus enters the host cells through receptor binding and membrane fusion between the viral and host cell membrane.

16 Jun 2020

Antibody cocktail is being tested in human COVID-19 trials

Following two studies that screened thousands of human antibodies to SARS-CoV-2 to identify highly potent pairs, in which both antibodies bind the viral target simultaneously, a resultant antibody cocktail is being tested in human trials.

16 Jun 2020

Testing reveals 11 percent of people in Geneva infected with SARS-CoV-2

Now, a team of researchers at Geneva University Hospitals has found that less than 11 percent of the population in Geneva has contracted the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Their research is published in the journal The Lancet.

15 Jun 2020

Controlling SARS-CoV-2 upon resumption of the Spanish football league

The coronavirus disease (COVID-19) pandemic first emerged in Wuhan City, China, in December 2019. Since then, it has spread throughout the world, infecting more than 8 million people. Social distancing measures were imposed in most countries, isolating people in their homes, banning congregations, including schools, parties, and even sports events.

15 Jun 2020

Human antibodies provide powerful protection against SARS-CoV-2 in animal tests

A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures.

15 Jun 2020

Tracing coronavirus habitats with genomics

Now, a new study by researchers at the University of Ottawa and published on the preprint server bioRxiv in June 2020 reports the differences in genomes of viruses that are exposed to antiviral proteins vs. those that are not. This host-derived pressure on the virus to adapt may help devise newer ways to build an effective vaccine.

15 Jun 2020

Inhaled steroids reduce ACE2 expression in COPD lungs

A new study by scientists at Imperial College London, University of Newcastle and Prokarium, and published on the preprint server bioRxiv* in June 2020 examines the role played by inhaled corticosteroids (ICS) in the risk of acquisition of COVID-19 infection by COPD patients.

15 Jun 2020

Trio of studies identifies new human antibodies that target SARS-CoV-2 virus

A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

15 Jun 2020

Genetic marker may predispose African Americans to cardiac complications from COVID-19

Nearly one out of every 10 African Americans has a genetic variant that puts them inherently at an increased risk for ventricular arrhythmias and sudden cardiac death.

15 Jun 2020

U.S. and European SARS CoV-2 mutation enhances transmission, increases infectivity

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the COVID-19 pandemic across the world has undergone a genetic mutation in the density of functional spikes on the virus, says a new study. This has led the virus to become highly infectious and easily transmissible between humans.

15 Jun 2020

Researchers report the prevalence of COVID-19 infections in pregnant women

Universal testing of pregnant women admitted to labor and delivery units is part of a multipronged approach to reducing transmission of the virus that causes COVID-19 in hospitals and clinics.

15 Jun 2020

Experimental drug to prevent deadly blood coagulation in patients with COVID-19

The British Heart Foundation is funding a trial for an experimental drug that could prevent the life-threatening blood clots that are seen in the lungs of the patients with COVID-19 or those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug named TRV027 is said to normalize the hormonal imbalance that can be seen in patients developing COVID-19, experts said.

15 Jun 2020

An inverse relationship between smoking and COVID-19

Researchers at the University of Washington and Stanford University School of Medicine have reported a significant inverse relationship between current smoking and coronavirus disease 2019 (COVID-19) mortality rates across forty countries.

15 Jun 2020